46 related articles for article (PubMed ID: 31597496)
1. First-line fulvestrant plus anastrozole for hormone-receptor-positive metastatic breast cancer in postmenopausal women: a cost-effectiveness analysis.
Liao W; Huang J; Wu Q; Wen F; Zhang N; Zhou K; Bai L; Li Q
Breast Cancer; 2020 May; 27(3):399-404. PubMed ID: 31853795
[TBL] [Abstract][Full Text] [Related]
2. Cost-effectiveness analysis of gemcitabine plus cisplatin versus docetaxel, cisplatin and fluorouracil for induction chemotherapy of locoregionally advanced nasopharyngeal carcinoma.
Wu Q; Liao W; Huang J; Zhang P; Zhang N; Li Q
Oral Oncol; 2020 Apr; 103():104588. PubMed ID: 32070923
[TBL] [Abstract][Full Text] [Related]
3. Adjuvant albumin-bound paclitaxel combined with S-1 vs. oxaliplatin combined with capecitabine after D2 gastrectomy in patients with stage III gastric adenocarcinoma: a phase III multicenter, open-label, randomized controlled clinical trial protocol.
Cheng X; Wu D; Xu N; Chen L; Yan Z; Chen P; Zhou L; Yu J; Cui J; Li W; Wang C; Feng W; Wei Y; Yu P; Du Y; Ying J; Xu Z; Yang L; Zhang Y
BMC Cancer; 2021 Jan; 21(1):56. PubMed ID: 33435909
[TBL] [Abstract][Full Text] [Related]
4. A phase II study of gemcitabine, erlotinib and S-1 in patients with advanced pancreatic cancer.
Han B; Kim BJ; Kim HS; Choi DR; Shim BY; Lee KH; Kim JW; Kim JH; Song H; Kim JH; Park CK; Lee JW; Kim MJ; Zang DY
J Cancer; 2021; 12(3):912-917. PubMed ID: 33403047
[No Abstract] [Full Text] [Related]
5. Randomized phase II study comparing the efficacy and safety of SOX versus mFOLFOX6 as neoadjuvant chemotherapy without radiotherapy for locally advanced rectal cancer (KSCC1301).
Miwa K; Oki E; Enomoto M; Ihara K; Ando K; Fujita F; Tominaga M; Mori S; Nakayama G; Shimokawa M; Saeki H; Baba H; Mori M; Akagi Y
BMC Cancer; 2021 Jan; 21(1):23. PubMed ID: 33402130
[TBL] [Abstract][Full Text] [Related]
6. The protocol of a prospective, multicenter, randomized, controlled phase III study evaluating different cycles of oxaliplatin combined with S-1 (SOX) as neoadjuvant chemotherapy for patients with locally advanced gastric cancer: RESONANCE-II trial.
Wang X; Li S; Sun Y; Li K; Shen X; Xue Y; Liang P; Li G; Chen L; Zhao Q; Li G; Fu W; Liang H; Xin H; Suo J; Fang X; Zheng Z; Xu Z; Chen H; Zhou Y; He Y; Huang H; Zhu L; Yang K; Ji J; Ye Y; Zhang Z; Li F; Wang X; Tian Y; Park S; Chen L
BMC Cancer; 2021 Jan; 21(1):20. PubMed ID: 33402102
[TBL] [Abstract][Full Text] [Related]
7. Adjuvant and neoadjuvant therapy for biliary tract cancer: a review of clinical trials.
Nara S; Esaki M; Ban D; Takamoto T; Shimada K; Ioka T; Okusaka T; Ishii H; Furuse J
Jpn J Clin Oncol; 2020 Dec; 50(12):1353-1363. PubMed ID: 33037430
[TBL] [Abstract][Full Text] [Related]
8. Phase I/II study of adding intraperitoneal paclitaxel in patients with pancreatic cancer and peritoneal metastasis.
Yamada S; Fujii T; Yamamoto T; Takami H; Yoshioka I; Yamaki S; Sonohara F; Shibuya K; Motoi F; Hirano S; Murakami Y; Inoue H; Hayashi M; Murotani K; Kitayama J; Ishikawa H; Kodera Y; Sekimoto M; Satoi S
Br J Surg; 2020 Dec; 107(13):1811-1817. PubMed ID: 32638367
[TBL] [Abstract][Full Text] [Related]
9. Valuation of EQ-5D-5L health states from cancer patients' perspective: a feasibility study.
Chai Q; Yang Z; Liu X; An D; Du J; Ma X; Rand K; Wu B; Luo N
Eur J Health Econ; 2023 Oct; ():. PubMed ID: 37837519
[TBL] [Abstract][Full Text] [Related]
10. A Novel Ferroptosis-Related Gene Signature Predicts Recurrence in Patients With Pancreatic Ductal Adenocarcinoma.
Feng Z; Chen P; Li K; Lou J; Wu Y; Li T; Peng C
Front Mol Biosci; 2021; 8():650264. PubMed ID: 34631790
[No Abstract] [Full Text] [Related]
11. Cost-Effectiveness Analysis of Olaparib Maintenance Treatment for Germline BRCA-Mutated Metastatic Pancreatic
Li N; Zheng H; Huang Y; Zheng B; Cai H; Liu M
Front Pharmacol; 2021; 12():632818. PubMed ID: 33959007
[No Abstract] [Full Text] [Related]
12. Adjuvant chemotherapy of S-1 versus gemcitabine for resected pancreatic cancer: a phase 3, open-label, randomised, non-inferiority trial (JASPAC 01).
Uesaka K; Boku N; Fukutomi A; Okamura Y; Konishi M; Matsumoto I; Kaneoka Y; Shimizu Y; Nakamori S; Sakamoto H; Morinaga S; Kainuma O; Imai K; Sata N; Hishinuma S; Ojima H; Yamaguchi R; Hirano S; Sudo T; Ohashi Y;
Lancet; 2016 Jul; 388(10041):248-57. PubMed ID: 27265347
[TBL] [Abstract][Full Text] [Related]
13. Cost-effectiveness analysis of FOLFIRINOX vs gemcitabine with nab-paclitaxel as adjuvant treatment for resected pancreatic cancer in the United States based on PRODIGE-24 and APACT trials.
Kharat AA; Nelson R; Au T; Biskupiak J
J Manag Care Spec Pharm; 2021 Oct; 27(10):1367-1375. PubMed ID: 34595948
[No Abstract] [Full Text] [Related]
14. Cost-effectiveness analysis of gemcitabine, S-1 and gemcitabine plus S-1 for treatment of advanced pancreatic cancer based on GEST study.
Zhou J; Zhao R; Wen F; Zhang P; Tang R; Du Z; He X; Zhang J; Li Q
Med Oncol; 2015 Apr; 32(4):121. PubMed ID: 25788034
[TBL] [Abstract][Full Text] [Related]
15. The clinical effectiveness and cost-effectiveness of gemcitabine for metastatic breast cancer: a systematic review and economic evaluation.
Takeda AL; Jones J; Loveman E; Tan SC; Clegg AJ
Health Technol Assess; 2007 May; 11(19):iii, ix-xi, 1-62. PubMed ID: 17462169
[TBL] [Abstract][Full Text] [Related]
16. Topotecan, pegylated liposomal doxorubicin hydrochloride, paclitaxel, trabectedin and gemcitabine for advanced recurrent or refractory ovarian cancer: a systematic review and economic evaluation.
Edwards SJ; Barton S; Thurgar E; Trevor N
Health Technol Assess; 2015 Jan; 19(7):1-480. PubMed ID: 25626481
[TBL] [Abstract][Full Text] [Related]
17. S-1 or gemcitabine adjuvant therapy in resected pancreatic cancer: a cost-effectiveness analysis based on the JASPAC-01 trial.
Liao W; Huang J; Zhu G; Zhou J; Wen F; Zhang P; Zhou K; Wu Q; Wang X; Gou H; Li Q
Expert Rev Pharmacoecon Outcomes Res; 2020 Feb; 20(1):133-138. PubMed ID: 31597496
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
